4basebio
Angel J. Picher currently serves as the Director of R&D at 4basebio, a position held since January 2020. Prior to this role, Angel was the Director of Genomics Research at Expedeon from January 2017 to January 2020. Angel has extensive experience in product development and project management, having worked as the Associate Director, Product Development and Project Manager at SYGNIS from October 2012 to December 2016 and as a Project Manager at X-Pol Biotech from May 2008 to October 2012. Angel began a career in scientific research as a Postdoctoral Scientist at Centro de Biología Molecular Severo Ochoa from April 2007 to May 2008. Angel holds a Doctor of Philosophy (PhD) in Molecular Biology from Universidad Autónoma de Madrid (2002-2007) and a Master of Science (MSc) in Biochemistry from Universidad Francisco de Vitoria (1997-2002).
This person is not in any offices
4basebio
4basebio is enabling next generation cell and gene therapies and vaccines with its technologies and solutions. We are able to design, manufacture and supply application-specific synthetic DNA or mRNA as well as targeted non-viral vectors for the delivery of nucleic acid payloads. Our novel synthetic DNA technology offers unique customisation potential, rapid turn-around times, and improved safety profiles, addressing the current limitations of plasmids and other DNA technologies. We currently offer four DNA construct types, each ideally suited for use in viral and non-viral vector applications, genome editing, vaccines and therapeutics, and DNA vaccine applications, respectively. Our proprietary non-viral delivery system, Hermes™, is a nanoparticle vector that can be customised to target cells or tissues of interest for a range of applications. This combines the safety and efficiency of lipid-based nanoparticles (LNPs) with the specificity of a targeting system, addressing the shortcoming associated with both viral vectors and non-targeted LNPs.